{"id":70584,"date":"2026-07-24T20:24:38","date_gmt":"2026-07-24T12:24:38","guid":{"rendered":"https:\/\/flcube.com\/?p=70584"},"modified":"2026-07-24T20:24:38","modified_gmt":"2026-07-24T12:24:38","slug":"roche-reports-6-h1-sales-growth-to-chf-30-4b-reaffirms-full-year-guidance-amid-strong-pharmaceutical-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70584","title":{"rendered":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) delivered robust first-half 2026 financial results on <strong>July 23, 2026<\/strong>, with <strong>group sales rising 6%<\/strong> to <strong>CHF 30,364 million<\/strong> (USD 37.2 billion) at constant exchange rates (CER). The company reported <strong>core operating profit growth of 10%<\/strong> to <strong>CHF 11,856 million<\/strong> (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.<\/p>\n\n\n\n<h2 id=\"h-financial-highlights-h1-2026\" class=\"wp-block-heading\">Financial Highlights \u2013 H1 2026<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Result<\/th><th>Growth (CER)<\/th><\/tr><\/thead><tbody><tr><td><strong>Group Sales<\/strong><\/td><td>CHF 30,364M (USD 37.2B)<\/td><td>+6%<\/td><\/tr><tr><td><strong>Core Operating Profit<\/strong><\/td><td>CHF 11,856M (USD 14.5B)<\/td><td>+10%<\/td><\/tr><tr><td><strong>Pharmaceutical Sales<\/strong><\/td><td>CHF 23,629M (USD 28.9B)<\/td><td>+6%<\/td><\/tr><tr><td><strong>Diagnostics Sales<\/strong><\/td><td>CHF 6,735M (USD 8.2B)<\/td><td>+3%<\/td><\/tr><tr><td><strong>Top 5 Growth Drivers<\/strong><\/td><td>CHF 11.0B<\/td><td>+12%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-pharmaceutical-portfolio-performance\" class=\"wp-block-heading\">Pharmaceutical Portfolio Performance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Key Growth Drivers:<\/strong> Roche&#8217;s top five pharmaceutical products delivered exceptional performance:<\/li>\n\n\n\n<li><strong>Xolair<\/strong> (omalizumab): allergic asthma, chronic hives, food allergies<\/li>\n\n\n\n<li><strong>Hemlibra<\/strong> (emicizumab): haemophilia A<\/li>\n\n\n\n<li><strong>Ocrevus<\/strong> (ocrelizumab): multiple sclerosis<\/li>\n\n\n\n<li><strong>Phesgo<\/strong> (trastuzumab\/pertuzumab): breast cancer<\/li>\n\n\n\n<li><strong>Vabysmo<\/strong> (Faricimab): severe eye diseases<\/li>\n\n\n\n<li><strong>Combined Impact:<\/strong> These five products generated <strong>CHF 11.0 billion<\/strong> in sales, representing <strong>12% growth<\/strong> at CER and accounting for nearly half of total pharmaceutical revenue<\/li>\n\n\n\n<li><strong>Therapeutic Diversity:<\/strong> Strong performance across immunology, hematology, neurology, oncology, and ophthalmology demonstrates portfolio resilience and reduced dependency on single therapeutic areas<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-diagnostics-segment-analysis\" class=\"wp-block-heading\">Diagnostics Segment Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Growth Trajectory:<\/strong> Diagnostics sales increased <strong>3%<\/strong> to <strong>CHF 6,735 million<\/strong>, reflecting steady demand across key segments<\/li>\n\n\n\n<li><strong>Demand Drivers:<\/strong> Growth was fueled by continued investment in:<\/li>\n\n\n\n<li><strong>Immunodiagnostic solutions<\/strong><\/li>\n\n\n\n<li><strong>Clinical chemistry platforms<\/strong><\/li>\n\n\n\n<li><strong>Pathology systems<\/strong><\/li>\n\n\n\n<li><strong>Molecular diagnostic technologies<\/strong><\/li>\n\n\n\n<li><strong>Market Position:<\/strong> Roche maintains its leadership position in the global diagnostics market, benefiting from integrated healthcare trends and precision medicine adoption<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-guidance-amp-strategic-outlook\" class=\"wp-block-heading\">Forward Guidance &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Year Expectations:<\/strong> Roche <strong>reaffirms its 2026 guidance<\/strong>:<\/li>\n\n\n\n<li><strong>Group sales growth:<\/strong> mid-single-digit range (CER)<\/li>\n\n\n\n<li><strong>Core EPS growth:<\/strong> high-single-digit range (CER)<\/li>\n\n\n\n<li><strong>Shareholder Returns:<\/strong> The company plans a <strong>further dividend increase in Swiss francs<\/strong>, continuing its commitment to returning value to shareholders<\/li>\n\n\n\n<li><strong>Pipeline Momentum:<\/strong> Strong H1 performance provides confidence in the company&#8217;s ability to execute on late-stage pipeline assets and maintain growth trajectory beyond 2026<\/li>\n\n\n\n<li><strong>Currency Impact:<\/strong> All growth figures reported at constant exchange rates, providing clear visibility into underlying business performance independent of forex volatility<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-positioning\" class=\"wp-block-heading\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pharmaceutical Industry Trends:<\/strong> Roche&#8217;s diversified portfolio strategy contrasts with peers facing patent cliffs, positioning the company favorably in the current market environment<\/li>\n\n\n\n<li><strong>Innovation Investment:<\/strong> Continued strong profitability enables sustained R&amp;D investment, with the company maintaining one of the industry&#8217;s highest research intensity ratios<\/li>\n\n\n\n<li><strong>Integrated Healthcare Model:<\/strong> The combination of pharmaceuticals and diagnostics creates unique competitive advantages in precision medicine and companion diagnostic development<\/li>\n\n\n\n<li><strong>Geographic Diversification:<\/strong> Balanced exposure across North America, Europe, and international markets provides stability against regional economic fluctuations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, growth expectations, and strategic initiatives. Actual results may differ due to regulatory developments, competitive pressures, and macroeconomic conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/260723_ir_hy-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 260723_ir_hy (1).\"><\/object><a id=\"wp-block-file--media-777e851a-e1d6-46be-ba43-5ba0436fa6c6\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/260723_ir_hy-1.pdf\">260723_ir_hy (1)<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/260723_ir_hy-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-777e851a-e1d6-46be-ba43-5ba0436fa6c6\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70586,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[27,940,163,939],"class_list":["post-70584","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70584\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70584\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-24T12:24:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance\",\"datePublished\":\"2026-07-24T12:24:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584\"},\"wordCount\":459,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2402.webp\",\"keywords\":[\"Finanical Reports\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70584#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70584\",\"name\":\"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2402.webp\",\"datePublished\":\"2026-07-24T12:24:38+00:00\",\"description\":\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70584\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2402.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2402.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70584#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70584","og_locale":"en_US","og_type":"article","og_title":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance","og_description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.","og_url":"https:\/\/flcube.com\/?p=70584","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-24T12:24:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70584#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70584"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance","datePublished":"2026-07-24T12:24:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70584"},"wordCount":459,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70584#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","keywords":["Finanical Reports","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70584#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70584","url":"https:\/\/flcube.com\/?p=70584","name":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70584#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70584#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","datePublished":"2026-07-24T12:24:38+00:00","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70584#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70584"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70584#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","width":1080,"height":608,"caption":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70584#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche Reports 6% H1 Sales Growth to CHF 30.4B, Reaffirms Full-Year Guidance Amid Strong Pharmaceutical Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2402.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70584"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70584\/revisions"}],"predecessor-version":[{"id":70587,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70584\/revisions\/70587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70586"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70584"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}